Head-to-head evidence
BCD-132 vs Ublituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
BCD-132
Developed by Biocad
NCT05385744 · Phase 3 · completed
Randomized, double-blind, active-controlled Phase 3 trial (n=480) showing superior relapse reduction vs teriflunomide (PMID 38676683).
Ublituximab
Marketed by TG THERAPEUTICS, INC.
NCT03277261 · Phase 3 · completed
This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).
Next expected readout: October 2026 · NCT07211633 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-132's landscape · Ublituximab's landscape